Bay Area startup Cartography Biosciences has closed a $67 million Series B financing led by Pfizer Ventures, aimed at advancing its pipeline of T-cell engaging bispecific and multispecific antibodies targeting novel colorectal cancer antigens. The company's approach leverages platform technologies to identify cancer-specific targets through healthy and cancer cell data analysis, potentially enabling differentiated and versatile immunotherapies. This financing positions Cartography to advance its lead programs toward the clinic and expand precision oncology options for colorectal cancer patients.